chronic inflammatory demyelinating polyneuropathy

News

Stop sign with green fields in the background

Sanofi abandons phase 3 trial of neurology drug riliprubart

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

News

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t

News

FDA starts review of Argenx drug in rare disease CIDP

The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the compan

Sanofi abandons phase 3 trial of neurology drug riliprubart

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

FDA starts review of Argenx drug in rare disease CIDP

Moderna builds commercial muscle as new launches loom

Discover a new era of healthcare panel engagement: Grounded ...

chronic inflammatory demyelinating polyneuropathy

Editor's Picks